Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lefamulin - Nabriva Therapeutics

Drug Profile

Lefamulin - Nabriva Therapeutics

Alternative Names: BC-3781; BC-3781.Ac; Lefamulin-acetate; SNV-001; XENLETA

Latest Information Update: 15 Dec 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Nabriva Therapeutics
  • Developer Nabriva Therapeutics; Sinovant Sciences; Sumitomo Pharmaceuticals; Sunovion Pharmaceuticals Canada
  • Class Alkenes; Anti-infectives; Anti-inflammatories; Antibacterials; Antifibrotics; Cyclopentanes; Diterpenes; Polycyclic compounds; Small molecules; Thioglycolates
  • Mechanism of Action Immunomodulators; Peptidyltransferase modulators; Protein 50S ribosomal subunit modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Community-acquired pneumonia
  • Phase II Skin and soft tissue infections
  • Phase I/II Mycoplasma infections
  • Phase I Cystic fibrosis
  • Preclinical Inflammation
  • No development reported Bacterial infections; Bone and joint infections; Nosocomial pneumonia; Osteomyelitis; Sexually transmitted infections

Most Recent Events

  • 04 Dec 2023 Nabriva Therapeutics terminates a phase I/II trial in Mycoplasma infections in USA at sponsor's request (NCT05111002)
  • 10 Feb 2023 Nabriva Therapeutics suspends a phase I/II trial in Mycoplasma infections in USA at sponsor request (NCT05111002)
  • 13 Jan 2023 Nabriva Therapeutics completes a phase I trial in Cystic Fibrosis in USA (IV), (PO) (NCT05225805)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top